Aerodynamic characterization of marketed inhaler dosage forms: High performance liquid chromatography assay method for the determination of budesonide

African Journal of Pharmacy and Pharmacology

Volumn 4, Issue 12, 2010, Pages 878-884

  Sahib, Mohanad Naji ^a   Darwis, Yusrida ^a   Khiang, Peh Kok ^a   Tan, Yvonne Tze Fung ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Aerodynamic diameter; Assay; HPLC; Impactor; Inhalation; Pulmicort

Indexed keywords

BUDESONIDE;

ACCURACY; AEROSOL; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG DETERMINATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHALER; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; RADIATION DETECTION; SENSITIVITY ANALYSIS; ULTRAVIOLET RADIATION; VALIDATION STUDY;

EID: 79951806523     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Abdulla J, Tan Y, Darwis Y (2010). Rehydrated Lyophilized Rifampicin- Loaded mPEG-DSPE Formulations for Nebulization. AAPS Pharm. SciTech, 11: 663-671.
2. Amani A, York P, Chrystyn H, Clark B (2010). Evaluation of a Nanoemulsion-Based Formulation for Respiratory Delivery of Budesonide by Nebulizers. AAPS Pharm. Sci. Tech, DOI:10.1208/s12249-010-9486-9.
3. Assi KH, Tarsin W, Chrystyn H (2006). High performance liquid chromatography assay method for simultaneous quantitation of formoterol and budesonide in Symbicort Turbuhaler. J. Pharm. Biomed. Anal., 41: 325-328.
4. Balaji K, Reddy G, Reddy T, Reddy S (2008). Determination of prednisolone, dexamethasone and hydrocortisone in pharmaceutical formulations and biological fluid samples by voltammetric techniques using -cyclodextrin modified carbon paste electrode. (AJPP), Afr. J. Pharm. Pharacol., 2: 157-166.
5. Bate R, Tren R, Hess K, Mooney L, Porter K (2009). Pilot study comparing technologies to test for substandard drugs in field settings. (AJPP), Afr. J. Pharm. Pharacol., 3: 165-170.
6. Berg EB, Picard RJ (2009). In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir. Care., 54: 1671-1678.
7. Berger W (2009). Aerosol devices and asthma therapy. Curr. Drug Deliv., 6: 38-49.
8. Bisgaard H (1998). Automatic Actuation of a Dry Powder Inhaler into a Nonelectrostatic Spacer. Am. J. Respir. Crit. Care Med., 157: 518-521.
9. Darwis Y, Kellaway IW (2001). Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes. Int. J. Pharm., 215: 113-121.
10. D'Cruz D (2003). Principles of Corticosteroid Therapy. J. R. Soc. Med., 96: 154.
11. Engel T, Heinig J, Madsen F, Nikander K (1990). Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur. Respir. J., 3: 1037-1041.
12. Epshtein N (2004). Validation of HPLC techniques for pharmaceutical analysis. Pharm. Chem. J., 38: 212-228.
13. Feddah MR, Brown KF, Gipps EM, Davies NM (2000). In-vitro characterization of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J. Pharm. Pharmaceut. Sci., 3: 318-24.
14. Gibson PG, Saltos N, Fakes K (2001). Acute Anti-inflammatory Effects of Inhaled Budesonide in Asthma. A Randomized Controlled Trial. Am. J. Respir. Crit. Care Med., 163: 32-36.
15. Gupta M, Bhargava HN (2006). Development and validation of a highperformance liquid chromatographic method for the analysis of budesonide. J. Pharm. Biomed. Anal., 40: 423-428.
16. International Conference on Harmonization (ICH) (2005).Validation of analytical procedures: text and methodology Q2 (R1), http://www.ich.org/cache/compo/363-272-1.html. (Accessed: 1st of August 2010).
17. Jenke D (1996). Chromatographic Method Validation: A Review of Current Practices and Procedures. II. Guidelines for Primary Validation Parameters. J. Liq. Chrom. Rel. Technol., 19: 737-757.
18. Liljelind I, Michel I, Damm M, Eriksson K (2007). Development, evaluation and data acquired with a tape-stripping technique for measuring dermal exposure to Budesonide at a pharmaceutical manufacturing site. Ann. Occup. Hyg., 51: 407.
19. Mitchell J, Newman S, Chan H-K (2007). In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review. AAPS. Pharm. Sci. Tech., 8: 237-248.
20. Naikwade S, Bajaj A (2008). Development of validated specific HPLC method for budesonide and characterization of its alkali degradation product. Can. J. Anal. Sci. Spect., 53: 113-122.
21. Neue UD, Alden B, Iraneta PC, Alberto M, Grumbach ES, Tran K & Diehl DM (2005). HPLC Columns for Pharmaceutical Analysis. In: Ahuja S & Dong MW (eds.) Handbook of pharmaceutical analysis by HPLCS. London: Elsevier academic press, pp. 98-102.
22. Peter WB, Chris OC (1999). An in vitro analysis of the output of budesonide from different nebulizers. J. Allergy Clin. Immunol., 104: 1168-1173.
23. Rao B, Nikalje A (2009). Stability-indicating HPLC method for the determination of efavirenz in bulk drug and in pharmaceutical dosage form. (AJPP), Afr. J. Pharm. Pharmacol., 3: 643-650.
24. Sahib M, Abdulameer S, Rasool A (2009). Design and in viro evaluation of prednisolone tables as a potential colon delivery system. AJPCR, 2: 84-93.
25. Sheshala R, Darwis Y, Khan N (2009). Development and Validation of an RP-LC-UV Method for the Determination of Ondansetron: Application to Pharmaceutical Dosage Forms. Chromatographia, 70: 75-81.
26. ® per Aerosol). Pulm. Pharmacol. Ther., 18: 151-153.
27. Wiggins NA (1991). The Development of a Mathematical Approximation Technique to Determine the Mass Median Aerodynamic Diameter (MMAD) and Geometric Standard Deviation (GSD) of Drug Particles in an Inhalation Aerosol Sprat. Drug Dev. Ind. Pharm., 17: 1971-1986.